Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 3Neuroblastoma 2Recurrence 1Non-Small Cell Lung Cancer ALK-positive 1Non Small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Glioma 1Glioblastoma 1Ganglioneuroblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma 1Brain Neoplasms 1Astrocytoma 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

pembrolizumab 105Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 46Nivolumab 43Paclitaxel 36Gemcitabine 30Radiosurgery 29Carboplatin 29Ipilimumab 24Irinotecan 22Cyclophosphamide 22Cisplatin 22trastuzumab deruxtecan 21Capecitabine 20Leucovorin 19Pemetrexed 18Fulvestrant 18Fluorouracil 18Cetuximab 18130-nm albumin-bound paclitaxel 18Docetaxel 17Bevacizumab 17Taxes 16Oxaliplatin 16Drug Therapy 16olaparib 15abemaciclib 14Radiotherapy 14Trastuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × lorlatinib × 1 year × Clear all
NCT06007937 2026-04-08

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Recruiting
56 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡